

Mattia Capulli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7395893/publications.pdf>

Version: 2024-02-01

41
papers

1,263
citations

394286

19
h-index

454834

30
g-index

41
all docs

41
docs citations

41
times ranked

2350
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteoblast and osteocyte: Games without frontiers. Archives of Biochemistry and Biophysics, 2014, 561, 3-12.	1.4	266
2	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	3.1	116
3	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer, 2014, 14, 154.	1.1	92
4	Generation and culture of osteoclasts. BoneKEy Reports, 2014, 3, 570.	2.7	87
5	Lipocalin 2: A New Mechanoresponding Gene Regulating Bone Homeostasis. Journal of Bone and Mineral Research, 2015, 30, 357-368.	3.1	76
6	The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF- κ B inhibitor that impairs osteoclastogenesis. Journal of Cell Biology, 2009, 187, 669-683.	2.3	72
7	Global transcriptome analysis in mouse calvarial osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a "mechanoresponsive osteoblast gene signature". Journal of Cellular Biochemistry, 2009, 107, 240-252.	1.2	63
8	Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. British Journal of Cancer, 2019, 121, 157-171.	2.9	59
9	β -Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice. Journal of Bone and Mineral Research, 2009, 24, 775-784.	3.1	37
10	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone, 2014, 59, 66-75.	1.4	36
11	A Complex Role for Lipocalin 2 in Bone Metabolism: Global Ablation in Mice Induces Osteopenia Caused by an Altered Energy Metabolism. Journal of Bone and Mineral Research, 2018, 33, 1141-1153.	3.1	36
12	Interleukin-1 β , lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk. Scientific Reports, 2016, 6, 29880.	1.6	35
13	Non-conventional role of haemoglobin beta in breast malignancy. British Journal of Cancer, 2017, 117, 994-1006.	2.9	31
14	TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Scientific Reports, 2018, 8, 39.	1.6	30
15	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. Journal of Bone and Mineral Research, 2012, 27, 2387-2398.	3.1	24
16	Biotechnological approach for systemic delivery of membrane Receptor Activator of NF- κ B Ligand (RANKL) active domain into the circulation. Biomaterials, 2015, 46, 58-69.	5.7	23
17	Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. Journal of Bone and Mineral Research, 2013, 28, 1912-1924.	3.1	21
18	Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. Molecular Therapy - Nucleic Acids, 2015, 4, e248.	2.3	21

#	ARTICLE	IF	CITATIONS
19	RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development. <i>Bone</i> , 2018, 110, 343-354.	1.4	20
20	NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. <i>Molecular Biology of the Cell</i> , 2012, 23, 2028-2040.	0.9	19
21	The C-Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1833-1846.	3.1	17
22	Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. <i>Cancer Letters</i> , 2020, 488, 27-39.	3.2	15
23	The $\hat{\pm}2\hat{2}^1$ binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study. <i>Cancer Letters</i> , 2015, 358, 67-75.	3.2	13
24	Extra-skeletal manifestations in mice affected by <i>Clcn7</i> -dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications. <i>Bone Research</i> , 2019, 7, 17.	5.4	12
25	Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading. <i>Calcified Tissue International</i> , 2019, 104, 344-354.	1.5	12
26	<sc>CRELD2</sc> Is a Novel <sc>LRP1</sc> Chaperone That Regulates Noncanonical <sc>WNT</sc> Signaling in Skeletal Development. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1452-1469.	3.1	12
27	Regulation of breast cancer induced bone disease by cancer-specific $IKK\hat{2}$. <i>Oncotarget</i> , 2018, 9, 16134-16148.	0.8	6
28	The Vicious Cycle of Breast Cancer-Induced Bone Metastases, a Complex Biological and Therapeutic Target. <i>Current Molecular Biology Reports</i> , 2018, 4, 123-131.	0.8	5
29	Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice. <i>PLoS ONE</i> , 2019, 14, e0213660.	1.1	5
30	MECHANISMS INDUCING LOW BONE DENSITY IN DUCHENNE MUSCULAR DYSTROPHY. <i>Bone</i> , 2010, 46, S79-S80.	1.4	1
31	Small interfering RNAs as an innovative therapeutic approach for the autosomal dominant osteopetrosis type 2 (ADO2). <i>Bone Abstracts</i> , 0, , .	0.0	1
32	P50. Osteotropic poly(d,l-lactide-co-glycolide)-alendronate nanoparticles for the treatment of bone cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 38.	3.4	0
33	The N-terminal domain of the bone protein P \hat{R} oline/arginine-rich End Leucine-rich repeat Protein (PRELP) impairs osteoclast formation by a new mechanism inhibiting NF- $\hat{\kappa}$ B signaling. <i>Bone</i> , 2010, 46, S64-S65.	1.4	0
34	The glycosaminoglycan-binding domain of PRELP acts as a cell type- $\hat{\epsilon}$ specific NF- $\hat{\kappa}$ B inhibitor that impairs osteoclastogenesis. <i>Journal of Experimental Medicine</i> , 2009, 206, i32-i32.	4.2	0
35	Involvement of the co-receptor RAMP2 in the progression of breast cancer-induced osteolytic lesions. <i>Bone Abstracts</i> , 0, , .	0.0	0
36	Multidisciplinary studies of ancient calcified tissues: renal stones from mummies. <i>Bone Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
37	multidisciplinary studies of ancient calcified tissues II: contents from Egyptian canopic jars. Bone Abstracts, 0, , .	0.0	0
38	The critical biomechanical role of Lipocalin 2 in the crosstalk between endothelium and osteoblasts in unloading conditions.. Bone Abstracts, 0, , .	0.0	0
39	Connecting the dots between bone and energy metabolism: the role of Lipocalin 2. Bone Abstracts, 0, , .	0.0	0
40	Storage disease and neurological phenotype in autosomal dominant osteopetrosis type 2 (ADO2). A preclinical study. Bone Abstracts, 0, , .	0.0	0
41	The role of Creld2 in skeletal development and homeostasis. Bone Abstracts, 0, , .	0.0	0